Angiogenin efficacy in therapy of venous trophic ulcers (the author's own experience
DOI: 10.32364/2587-6821-2025-9-9-19
E.A. Sukhorukov
Healthy generation LLC, Podolsk, Russian Federation
Recent studies have shown a key role of imbalance between extracellular matrix degradation and angiogenesis in pathogenesis of venous trophic ulcers (VTUs), as well as a significant increase in serum angiogenin levels in this category of patients. The author presents his own experience of combined therapy for VTUs with injectable and local recombinant angiogenin in 4 patients aged 50–86 years with comorbidities who were resistant to conventional treatment. In one case, the injections were combined with platelet-rich plasma (PRP). Wound defect area alteration, as well as granulation and complete healing time were efficacy ctiteria. All the presented clinical case reports showed significant improvement. Within 3–4 weeks, active appearance of granulation tissue and epithelialization onset were reported. Complete healing of the ulcers was achieved in 3 patients within 2–4 months. Angiogenin therapy demonstrated high efficacy in reparation stimulation in recurrent VTUs. Therefore, it may be considered as a promising adjuvant in combined therapy of this condition. The results are encouraging, and further large-scale controlled studies should be conducted.
Keywords: angiogenin, trophic ulcer, chronic venous insufficiency, angiogenesis, wound healing, growth factors, platelet-rich plasma, clinical case report.
For citation: Sukhorukov E.A. Angiogenin efficacy in therapy of venous trophic ulcers (the author's own experience). Russian Medical Inquiry. 2025;9(9):668–673 (in Russ.). DOI: 10.32364/2587-6821-2025-9-9-19
About the author:
Evgenyi A. Sukhorukov — Surgeon (Phlebologist), Ultrasound Doctor, Healthy generation LLC; 54/150, Fevralskaya str., Podolsk, 142100, Russian Federation; ORCID iD 0000-0002-6337-0629
Contact information: Evgenyi A. Sukhorukov, e-mail: 8896626@gmail.com
Financial Disclosure: the author has no a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 15.07.2025.
Revised 07.08.2025.
Accepted 28.08.2025.
2. Kolano P., Bednarski I.A., Kraska-Gacka M. et al. Serum concentration of matrix metalloproteinases and angiogenic factors in patients with venous leg ulcers. Postepy Dermatol Alergol. 2021;38(2):230–234. DOI: 10.5114/ada.2021.106201
3. Guo X., Li D. The emerging role of angiogenin in stress response and cell survival under adverse conditions. Front Physiol. 2012;3:424. DOI: 10.3389/fphys.2012.00424
4. Barrientos S., Brem H., Stojadinovic O., Tomic-Canic M. Clinical application of growth factors and cytokines in wound healing. Wound Repair Regen. 2014;22(5):569–578. DOI: 10.1111/wrr.12205
5. Lee Y., Lee M.H., Phillips S.A., Stacey М.C. Growth factors for treating chronic venous leg ulcers: A systematic review and meta-analysis. Wound Repair Regen. 2022;30(1):117–125. DOI: 10.1111/wrr.12982
6. Olson K.A., Fett J.W., French T.C. et al. Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci U S A. 1995;92(2):442–446. DOI: 10.1073/pnas.92.2.442
7. Ачкасов Е.Е., Безуглов Э.Н., Ульянов А.А. и др. Применение аутоплазмы, обогащенной тромбоцитами, в клинической практике. Биомедицина. 2013;(4):47–59.Achkasov E.E., Bezuglov E.N., Ul'yanov E.N. et al. Application platelet-rich plasma in clinical practice. Biomedicina. 2013;(4):47–59 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
